A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability

Xiangyang Chi; Renhong Yan; Jun Zhang; Guanying Zhang; Yuanyuan Zhang; Meng Hao; Zhe Zhang; Pengfei Fan; Yunzhu Dong; Yilong Yang; Zhengshan Chen; Yingying Guo; Jinlong Zhang; Yaning Li; Xiaohong Song; Yi Chen; Lu Xia; Ling Fu; Lihua Hou; Junjie Xu; Changming Yu; Jianmin Li; Qiang Zhou; Wei Chen.
Preprint en Inglés | PREPRINT-BIORXIV | ID: ppbiorxiv-083964

Documentos relacionados

  1. Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations.
  2. Targeting the Spike Receptor Binding Domain Class V Cryptic Epitope by an Antibody with Pan-Sarbecovirus Activity.
  3. Defining a de novo non-RBM antibody as RBD-8 and its synergistic rescue of immune-evaded antibodies to neutralize Omicron SARS-CoV-2.
  4. Dissection of Antibody Responses of Gam-COVID-Vac-Vaccinated Subjects Suggests Involvement of Epitopes Outside RBD in SARS-CoV-2 Neutralization.
  5. Characterization of a neutralizing antibody that recognizes a loop region adjacent to the receptor-binding interface of the SARS-CoV-2 spike receptor-binding domain.
  6. Structural Study of SARS-CoV-2 Antibodies Identifies a Broad-Spectrum Antibody That Neutralizes the Omicron Variant by Disassembling the Spike Trimer.
  7. Neutralization of SARS-CoV-2 requires antibodies against conformational receptor-binding domain epitopes.
  8. A natural mutation between SARS-CoV-2 and SARS-CoV determines neutralization by a cross-reactive antibody.
  9. A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern.
  10. Longitudinal immune profiling reveals dominant epitopes mediating long-term humoral immunity in COVID-19-convalescent individuals.